Alternative pre-mRNA splicing (AS) is a key molecular event that allows for protein diversity and plays important roles in development and disease. AS regulations during spermatogenesis and AS aetiology in testicular tumorigenesis have not yet to be characterized. By genome-wide analysis, here we describe alternative splicing features that distinguish distinctive patterns of AS among human testis, testicular cancer and mouse testis. Through computationally subtractive analysis, we detected 80 testis-specific transcript candidates in human testis, 175 in human testicular cancer and 262 in mouse testis, which were integrated into a database. RT-PCR confirmed that the most of these transcript candidates from mouse testis were testis-specific.
Introduction
Since the discovery that the coding information of metazoan genes is interrupted by introns [1, 2] , it still amazes how both intron removal and exon rearrangement are regulated precisely to produce correct proteomes in cell type-or developmental stage-specific manner. Alternative splicing, the process by which the exons of primary transcripts (pre-mRNAs) from genes can be spliced in different arrangements to produce structurally and functionally distinct mRNA and protein variants, is the most widely used mechanism to enhance protein diversity of higher eukaryotic organisms. It was estimated that around 35%-70% of all human genes appear to undergo alternative splicing [3] [4] [5] [6] [7] [8] . Comparable amounts of alternative splicing were also detected in the fly, nematode and other vertebrates [8, 9] , emphasizing its major role in the biology of all animals.
In certain pathological conditions aberrantly spliced pre-mRNAs can be generated that go unnoticed by the nonsense mediated mRNA decay (NMD) pathway, and are, therefore, translated into aberrant proteins, which are involved in several human diseases [10] [11] [12] . There have been also multifaceted studies into the relevance of alternative splicing to cancer at the level of individual genes and individual cancers [13] . Currently, the analysis of cancer-specific alternative splicing is a promising step forward in potential source for new clinical diagnostic, prognostic, and therapeutic strategies.
However, despite the growing interest on the impact of alternative splicing in various aspects of the biological processes, our understanding of alternative splicing is still very primitive and its regulatory mechanisms are mostly unknown [14, 15] . The unusually high levels of alternative splicing were often observed in the human brain and testis [16, 17] . Why is alternative splicing so abundant in the testis? Alternative splicing is probably very important throughout germ cell development. In order to advance our understanding of the biological significance of alternative splicing in humans testis and its tumorigenesis, it is essential to identify tissue-specific splicing events. Although tissue-specific alternative splicing patterns was analyzed by computationally 3 determined splice [8, 15, 16] , comparisons between normal and tumor, especially in human testis, combined with experimentally determined analysis, will provide more information on our understanding of human testicular tumorigenesis.
Here, we performed a genome-wide analysis of alternative splicing, combining with computationally subtractive screening and experimental verification, to compare tissue-specific alternative splicing patterns among human normal testis and testicular cancer, and mouse testis.
Our results distinguish distinctive patterns of alternative splicing, and identify pronounced differences in the chromosomal distribution, splice types and splice-/flanking-splice sites among the three kinds of tissues, suggesting multiple and even complex role of alternative splicing in human testicular tumorigenesis. (Table S1) , 30 s; and 72 °C, 30s for 35 cycles. All PCR products were resolved on 1.5% agarose gels run at 90 V/20 cm for 0.5 h in TBE buffer.
Materials and Methods

Data sources and filtration
Results
Detection of testis-specific alternative splicing
For of these genes contained at least one testis-specific transcript candidate, about 10 % of them had two, and a few of them had three to six transcripts ( Figure 1b) . We also analyzed overlapping among detected genes/transcripts in the three samples and found that there were only a few genes overlapped. 6 To see if there was chromosome preference of alternative splicing events, we further mapped these transcripts onto chromosomes. Based on chromosome locations of transcripts, we observed that alternative splicing events in human normal testis were rich on chromosome 1, 12, 17 and 20, however, in testis cancer, they displayed strong preference to chromosome 2, 11, 12, 19 and X (Figure 1c) . In mouse testis, alternative splicing events occurred mainly on chromosome 2, 7 and 17 although distributed on all chromosomes (Figure 1d ).
To facilitate future study and reference of alternatively spliced genes of mammals, we constructed a database based on our analysis, which contained 80 tissue-specific transcripts in human testis, 175 in human testicular cancer and 262 in mouse testis, of which, 40% were unknown/hypothetical genes. It gave an overview of testis-specific alternative splicing in human and mouse and was especially useful for further study on testis oncogenesis. To validate alternative splicing detected by the computational approaches, we designed RT-PCR primers to amplify testis-specific transcripts of mouse whose function information was not clear in public databases. Of 62 genes amplified, 26 transcripts were testis-specific (Figure 3a) and 23 were dominantly expressed in testis (Figure 3b ). The two groups accounted for 79% of all cases. Another 8 genes (16%) were ubiquitously expressed in the tested tissues (Figure 3c ). The remained 5 genes cannot be amplified in our validation. Reasons for this may be related to EST sequencing errors, splicing errors or improper primers. Predicted transcripts specific for testicular cancer were verified by RT-PCR, which showed that some were testis cancer-specific ( Figure   3e1 ), and some were expressed at equal or lower level in testis cancer (Figure 3e2) .
Patterns of the identified alternative splicing in testis
After comparisons between EST and genomic sequences on chromosomes, we detected five types 7 of alternative splicing patterns: cassette alternative exon, alternative 5' splice site, alternative 3' splice site, intron retention and mutually exclusive alternative exons (Figure 4a ). It was intriguing that the cassette alternative exon variants formed the most frequent category (50% of all the types). For example, by subtractive analysis, we detected that loss of the exon III by cassette alternative exon of mouse Tcte3 (t-complex-associated testis expressed 3) gene resulted in a testis-specific transcript 2 which deleted Tctex-1 domain (Figure 4c) . Similarly, deletion of the exon VI by cassette alternative exon of human TMBIM4 (trans-membrane BAX inhibitor motif containing 4) gene generated a testis-specific short form of transcript 2, which lost the 3' part of the domain UPF0005 (Figure 4d ). Alternative splicing may cause testis cancers. In support of this,
we detected a testis cancer-specific transcript 1 of human PRDX3 (peroxiredoxin 3) gene, which was produced by the alternative 5' and 3' splice sites (Figure 4e ). Indeed, we detected more than 110 of human testis cancer-specific alternatively splicing transcripts.
Comparisons of ratios of these types of alternative splicing patterns among human testis, testicular cancer and mouse testis showed that both alternative 3' splice site and intron retention had a higher proportion in cancer, however ratio of both cassette alternative exon and alternative 5' splice site decreased in cancer. In addition, in mouse testis, the type alternative 5' splice site was highest, while the cassette alternative exon was lowest among the three samples (Figure 4b ).
These results showed that there was significant preference in use of these types of alternative splicing in testicular cancer and mouse testis.
Diversification of the identified alternative splice-sites
To see preference/diversification of alternative splice-sites in these testis-expressed genes, we analyzed 1747 splice-sites in human testis, 5159 in human testicular cancer and 7002 in mouse testis by comparison of each EST with its genomic sequence and mapping it onto chromosome.
We detected four basic donor-acceptor splice sites: GT-AG, GC-AG, GG-AG and GT-GG, of which GT-AG was the most dominant site (90-93%) (Figure 5a ). Furthermore, several interesting points we found: 1) GG-AG was detected in both normal (0.38-0.47%) and cancer testis (0.74%). 8 2) GT-GG was only detected in cancer (0.45%) and mouse testis (0.19%), not in normal human testis. 3) Besides the four basic donor-acceptor splice sites, there were quite a number of rare sites especially in testicular cancer (6.31%). 4) 27% of the rare sites were shared by human testicular cancer and mouse testis, 21% of them were human testis cancer-specific, while only a few of them were normal human testis-specific (4%) ( Figure 5b ). These results suggested that the rare splice-sites may be involved in testis tumorigenesis, moreover, the most of these rare splice-sites were mouse-derived.
We further compared sequences adjacent dominant splice-sites among human testis cancer, testicular cancer and mouse testis. In 5' splice-site region, downstream dominant splice-site GT, though a consensus AAGT at position 3-6, less A at the position 3 (60%) and more AG at the position 4 (74%) and 5 (78%) were observed in testicular cancer compared with relevant positions in normal human testis (70%, 65% and 70% respectively) (Figure 6a ). In the upstream of the 3' splice-site AG, no preference of nucleotide at the -2 position and a C/T preference at the -1 position were observed in the three kinds of samples (Figure 6b ). However, obvious T preference from position -3 to -9 was detected in testicular cancer, especially at the position -9 (64%), while in normal human testis the positions with the T preference was wider upstream position -3, especially less T (57%) at the position -9 and more T at the position 10 (64%; cancer, 42%) and 11 (63%; cancer, 50%), and less obvious T preference in mouse testis was observed.
Discussion
We have developed a method for precisely delineating alternative splice patterns by alignment EST/cDNA sequences first, and comparing the ESTs/cDNAs with their genomic sequences, and then mapping them onto chromosomes. These procedures eliminated many EST errors, pseudogene and multiple-copy/repeat gene problems when data were from diverse EST databases.
Considering the fact that genome-wide studies found transposable elements (mainly Alus) in nearly 4% of human protein-coding regions [18] , the Alu repeats were not excluded in our 9 subtractive analysis. The alternatively spliced transcripts were subject to subtractive screening of testis versus all the other tissues, and these analyses finally yielded testis-specific transcripts.
Interestingly, about 40% of the transcripts were from unknown/hypothetical genes, which were useful to further functional analysis. RT-PCR analysis further confirmed the most of our computationally determined results. Nevertheless, there were a small number of transcripts from computationally subtractive results, which were ubiquitously expressed in the tested tissues. This may be caused by EST coverage, their fragmentary character and sequencing errors escaped from our analysis. In any case, we believe our database of 80 testis-specific transcript candidates in human testis, 175 in human testicular cancer and 262 in mouse testis can be a rich source of discovery for our studying spermatogenesis, and especially testicular tumorigenesis.
However, its major value is providing previously unknown patterns of alternative splicing in human testicular tumor. 1) Alternative splicing events in testicular tumor have chromosomal preference, a strong preference to chromosome 2, 11, 12, 19 and X. 2) Alternative splicing in human testicular tumor shares some characters/trends with those in mouse testis. For example, in the usage of types of alternative splicing, both human testicular cancer and mouse testis trend to use types of both alternative 3' splice site and intron retention. Moreover, a considerable number (27%) of the rare splice sites are shared by human testicular cancer and mouse testis, and genes involved in synthesis/degradation are frequently spliced in these two groups. 3) Human testicular tumor tends to use rare splice-sites. 4) There are distinct sequences adjacent dominant splice-sites in human testicular tumor. These special features of alternative splicing in human testicular tumor suggest that testicular tumorigenesis is involved in multiple steps/levels of alternative splicing events. This view is consistent with results observed in testicular germ-cell tumorigenesis, which is involved multiple aspects including somatic genetic changes, allelic imbalance, multiple gene mutations and methylation patterns [19] . Testicular cancer seems to need multiple genetic events to occur. Taken together, these data suggest a complex etiopathology of testicular tumorigenesis.
Our data include discovery of many novel splice forms of testicular cancer-associated genes, 10 alternative-splicing patterns of testicular cancer, and suggest a significant new direction for testicular cancer research.
Interestingly, these tissue-specific alternative splicing variants are not evolutionarily conserved between human and mouse. Whether would be the biological significance of their existence questionable? The same results were obtained to show that vast majority of alternative splicing events represented in the human EST database are not conserved in mouse [20] . Main explanation for this issue may be because most of these splicing events may represent tissue-, disease-specific, or allele-specific splicing, or events for which phylogenetic distribution is highly restricted. And alternative splicing could be also the easiest road to diversification of the species. We believe that species-specific alternative splicing represents a fascinating aspect of it that has undoubtedly had a major impact on genome evolution [21] . Moreover, analyses of substitution rates in the genomes of different mammalian species indicate that the exons of species-specific splice variants evolve more rapidly than constitutive or conserved alternatively spliced exons [22] .
Indeed, it will be important in future studies to decipher the interplay among species-specific alternative splicing, protein diversity, and pathogenic alternative splicing in cancer.
Main interest of this paper is data mining for testis-specific transcripts by the genome-wide identification and subtractive analysis of alternative splicing variants. Some of the testis cancer-specific splice forms we detected may be medically important. However, this should be further verified in detail by experimental approaches such micro-array analysis and functional analysis, so as to determine which are initial triggers of tumorigenesis or just reflections of transformed state, because at present time, some factors such as grade of aggressiveness, aging and stress were not considered owing to limitation of data sources. Indeed these factors affected the alternative splicing events [23] [24] [25] [26] . Computational analyses have gone some way to providing a global view of tissue-specific splicing, but these studies are limited by inadequate transcript coverage, by difficulties in assigning ESTs to tissue or cell types or sorting different categories.
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In conclusion, evidences are accumulating that just as alternative splicing is important for spermatogenesis, so aberrations of alternative splicing patterns are important for testicular cancer.
Testicular tumorigenesis needs multiple genetic events to occur; therefore, processes at the top of genetic hierarchies such as alternative splicing could be the cause, and the prospect that we might start to use alternative splicing as a potential source for new clinical diagnostic, prognostic, and therapeutic strategies. For example, novel therapeutic strategies could be designed to target the splicing machinery, which can be defective in some testicular tumours. Further efforts into alternative splicing aetiology in testicular cancer seem bright. were predicted. e, Six candidates specific for human testicular cancer were verified by RT-PCR. 15 (e1, three candidates s4030088, s4538854, s4414287 were testis cancer-specific, e2, three candidates s3377828, s3379385, s3458157 were expressed at equal or lower level in testis cancer). e, Human PRDX3 was alternative spliced by alternative 5'splice site and 3' splice site splicing to generate transcript 1 which is testis cancer-specific. 
